These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 7932431)

  • 1. Tachyphylaxis of intravenous immunoglobulin in refractory inflammatory myopathy.
    Reimold AM; Weinblatt ME
    J Rheumatol; 1994 Jun; 21(6):1144-6. PubMed ID: 7932431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies.
    Dalakas MC
    Clin Exp Immunol; 1996 May; 104 Suppl 1():55-60. PubMed ID: 8625545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of the dropped head/bent spine syndrome to treatment with intravenous immunoglobulin.
    Dominick J; Sheean G; Schleimer J; Wixom C
    Muscle Nerve; 2006 Jun; 33(6):824-6. PubMed ID: 16421882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
    Raju R; Dalakas MC
    Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.
    Göttfried I; Seeber A; Anegg B; Rieger A; Stingl G; Volc-Platzer B
    Eur J Dermatol; 2000; 10(1):29-35. PubMed ID: 10694294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin therapy for refractory myositis.
    Moriguchi M; Suzuki T; Tateishi M; Hara M; Kashiwazaki S
    Intern Med; 1996 Aug; 35(8):663-7. PubMed ID: 8894745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
    Sami N; Letko E; Androudi S; Daoud Y; Foster CS; Ahmed AR
    Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease.
    Chrissafidou A; Malek M; Musch E
    Z Gastroenterol; 2007 Jul; 45(7):605-8. PubMed ID: 17620224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A patient of recurrent orbital myositis with good response to high-dose intravenous immunoglobulin (i.v.-i.g.) therapy].
    Nakatani-Enomoto S; Aizawa H; Koyama S; Haga T; Takahashi J; Kikuchi K
    Rinsho Shinkeigaku; 2002 Feb; 42(2):154-7. PubMed ID: 12424967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
    Breems DA; de Haas PW; Visscher F; Sabbe LJ; Busch HF; van Doorn PA
    Ned Tijdschr Geneeskd; 1993 Sep; 137(39):1979-82. PubMed ID: 8413708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
    Ahmed AR
    J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment].
    Léger JM; Viala K; Maisonobe T; Bouche P
    Bull Acad Natl Med; 2007 Oct; 191(7):1395-407; discussion 1407-9. PubMed ID: 18447061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pyoderma gangrenosum with intravenous immunoglobulin.
    Cummins DL; Anhalt GJ; Monahan T; Meyerle JH
    Br J Dermatol; 2007 Dec; 157(6):1235-9. PubMed ID: 17916196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
    Ahmed AR
    J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunogenic myositis].
    Pongratz D
    Dtsch Med Wochenschr; 2006 Feb; 131(7):330-6; quiz 337-8. PubMed ID: 16468103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin.
    Soueidan SA; Dalakas MC
    Neurology; 1993 May; 43(5):876-9. PubMed ID: 8492940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum levels of interleukin-6 and interleukin-10 in patients with multiple sclerosis during intravenous immunoglobulin infusion].
    Kazibutowska Z; Motta E; Huć M; Strzała-Orzeł M; Woźnik G
    Wiad Lek; 2006; 59(9-10):626-9. PubMed ID: 17338118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab as therapy for refractory polymyositis and dermatomyositis.
    Noss EH; Hausner-Sypek DL; Weinblatt ME
    J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of IVIg treatment in severe pemphigus vulgaris.
    Baum S; Scope A; Barzilai A; Azizi E; Trau H
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):548-52. PubMed ID: 16684282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.